Korea United Pharm’s Sejong‑1 plant, located in Jeon‑dong‑myeon, Sejong Special Self‑Governning City, successfully passed an on‑site inspection by Ukraine’s pharmaceutical regulatory authority, confirming continued compliance with Good Manufacturing Practice (GMP) standards.
The facility originally received GMP approval from Ukrainian authorities in 2023, and the re‑inspection conducted in 2024 also resulted in a favorable assessment. Ukraine conducts GMP reviews using EU guidelines, according to the company.
The company also referenced a 2013 collaboration with multinational pharmaceutical firm TEVA, though details were not expanded in the source.
Regulatorische Updates14. Sept. 2026•3 Min. Lesezeit
Korea United Pharm’s Sejong Plant Retains GMP Certification after Ukrainian Inspection
Korea United Pharm announced that its Sejong‑1 plant passed a re‑inspection by Ukraine’s drug regulator, maintaining its GMP certification.
Zusammengestellt vom Pharmacountry-Team · Quelle: KPA News
Themen:
Bewertungen
(0)
(0)
(0)
(0)
(0)
Bewertung hinterlassen